The Expression of Mir-181B, Cyld, Cbx-7, Bcl2, and P53 in Osteosarcoma Patients and Correlation With Clinicopathological Factors

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share By

The Expression of Mir-181B, Cyld, Cbx-7, Bcl2, and P53 in Osteosarcoma Patients and Correlation With Clinicopathological Factors Publisher Pubmed

Fazli J¹ ; Fattah K² ; Moliani A³ ; Valizadeh A⁴ ; Bazavar M¹

Source: Chemical Biology and Drug Design Published:2023

Abstract

Osteosarcoma is a common human malignancy with a high mortality rate worldwide. Recent studies have been focused on understanding the involvement of microRNA (miRNAs) in the pathogenesis of osteosarcoma. Therefore, the present study aimed to measure the expression levels of miR-181a, cylindromatosis (CYLD), chromo box homolog 7 (CBX7), B-cell lymphoma 2 (BCL2), and tumor protein p53 in tumor tissue and adjacent normal tissues in patients with osteosarcoma and its relationship with clinicopathological factors. The expression levels of miR-181a, CYLD, CBX7, BCL2, and p53 were measured in 60 patients with osteosarcoma using quantitative real-time polymerase chain reaction. Finally, we compared the relationship between these gene levels and clinicopathological factors in tumor and healthy tissues. Our results showed that the expression levels of miR-181a, BCL2, and p53 were significantly higher in osteosarcoma tissue in comparison with normal tissues (p <.05). On the contrary, CYLD and CBX7 were downregulated in osteosarcoma tumor tissues compared to adjacent healthy tissues (p <.05). In addition, the expression levels of miR-181a in tumor tissues were strongly correlated with patients' age, tumor size, clinical stage, cancer grade, and lymph node metastasis (p <.05). Our findings highlight new insights into understanding the role of miR-181a in the pathogenesis of osteosarcoma. However, further studies are needed to elucidate miRNA as therapeutic targets for osteosarcoma. © 2022 John Wiley & Sons Ltd.

Related Docs

View other Related Docs

1. The Upregulation of Hsa-Mir-181B-1 and Downregulation of Its Target Cyld in the Late-Stage of Tumor Progression of Breast Cancer, Indian Journal of Clinical Biochemistry (2020)

2. Long Noncoding Rna-Mirna-Mrna Axes Multiple Roles in Osteosarcoma, Gene Reports (2021)

3. A Review on Expression and Regulatory Mechanisms of Mir-337-3P in Cancer, Journal of Biomolecular Structure and Dynamics (2024)

Experts (# of related papers)

View all Related Experts

Mazdak Ganjalikhani Hakemi (4)

Mohammadreza Sharifi (3)

Other Related Docs

4. Mir-574, Mir-499, Mir-125B, Mir-106A, and Mir-9 Potentially Target Tgfbr-1 and Tgfbr-2 Genes Involving in Inflammatory Response Pathway: Potential Novel Biomarkers for Chronic Lymphocytic Leukemia, Pathology Research and Practice (2022)

5. State of the Art in Microrna As Diagnostic and Therapeutic Biomarkers in Chronic Lymphocytic Leukemia, Journal of Cellular Physiology (2018)

6. Evaluation of the Effect of Tim-3 Suppression by Mir-498 and Its Effect on Apoptosis and Proliferation Rate of Hl-60 Cell Line, Pathology Research and Practice (2018)

7. Microrna-200C Overexpression in Cancer-Associated Fibroblasts Reduces the Invasive Properties of Breast Tumour Cells, Clinical and Translational Discovery (2022)

8. Expression of Hsa-Mir-204, Runx2, Pparγ, and Bcl2 in Bone Marrow Derived Mesenchymal Stem Cells From, Cell Journal (2017)

9. Circulating Micrornas in Hepatocellular Carcinoma: Potential Diagnostic and Prognostic Biomarkers, Current Pharmaceutical Design (2016)

10. Mir-370 Expression Analysis in Breast Cancer, Journal of Isfahan Medical School (2015)

11. Emerging Role of Mir-372 and Mir-101A in Head and Neck Squamous Cell Carcinoma, Clinical Laboratory (2020)

12. Microrna-184 in the Landscape of Human Malignancies: A Review to Roles and Clinical Significance, Cell Death Discovery (2023)

13. Dysregulated Expression and Functions of Microrna-330 in Cancers: A Potential Therapeutic Target, Biomedicine and Pharmacotherapy (2022)

14. Microrna in Leukemia: Tumor Suppressors and Oncogenes With Prognostic Potential, Journal of Cellular Physiology (2019)

15. Singe Nucleotide Polymorphisms in Osteosarcoma: Pathogenic Effect and Prognostic Significance, Experimental and Molecular Pathology (2019)

16. Circulating Microrna-192 As a Diagnostic Biomarker in Human Chronic Lymphocytic Leukemia, Cancer Gene Therapy (2016)

17. Antiproliferative Effect of Upregulation of Hsa-Let-7C-5P in Human Acute Erythroleukemia Cells, Cytotechnology (2018)

18. Plasma Level of Mir-21 and Mir-451 in Primary and Recurrent Breast Cancer Patients, Breast Cancer: Targets and Therapy (2019)

19. Inducing Cell Proliferative Prevention in Human Acute Promyelocytic Leukemia by Mir-182 Inhibition Through Modulation of Casp9 Expression, Biomedicine and Pharmacotherapy (2017)

20. The Mir-125A-3P Inhibits Tim-3 Expression in Aml Cell Line Hl-60 in Vitro, Indian Journal of Hematology and Blood Transfusion (2017)

Style	Citing Format
MLA	Fazli J, et al.. "The Expression of Mir-181B, Cyld, Cbx-7, Bcl2, and P53 in Osteosarcoma Patients and Correlation With Clinicopathological Factors." Chemical Biology and Drug Design, vol. 101, no. 1, 2023, pp. 2-8.
APA	Fazli J, Fattah K, Moliani A, Valizadeh A, Bazavar M (2023). The Expression of Mir-181B, Cyld, Cbx-7, Bcl2, and P53 in Osteosarcoma Patients and Correlation With Clinicopathological Factors. Chemical Biology and Drug Design, 101(1), 2-8.
Chicago	Fazli J, Fattah K, Moliani A, Valizadeh A, Bazavar M. "The Expression of Mir-181B, Cyld, Cbx-7, Bcl2, and P53 in Osteosarcoma Patients and Correlation With Clinicopathological Factors." Chemical Biology and Drug Design 101, no. 1 (2023): 2-8.
Harvard	Fazli J et al. (2023) 'The Expression of Mir-181B, Cyld, Cbx-7, Bcl2, and P53 in Osteosarcoma Patients and Correlation With Clinicopathological Factors', Chemical Biology and Drug Design, 101(1), pp. 2-8.
Vancouver	Fazli J, Fattah K, Moliani A, Valizadeh A, Bazavar M. The Expression of Mir-181B, Cyld, Cbx-7, Bcl2, and P53 in Osteosarcoma Patients and Correlation With Clinicopathological Factors. Chemical Biology and Drug Design. 2023;101(1):2-8.
BibTex	@article{ author = {Fazli J and Fattah K and Moliani A and Valizadeh A and Bazavar M}, title = {The Expression of Mir-181B, Cyld, Cbx-7, Bcl2, and P53 in Osteosarcoma Patients and Correlation With Clinicopathological Factors}, journal = {Chemical Biology and Drug Design}, volume = {101}, number = {1}, pages = {2-8}, year = {2023} }
RIS	TY - JOUR AU - Fazli J AU - Fattah K AU - Moliani A AU - Valizadeh A AU - Bazavar M TI - The Expression of Mir-181B, Cyld, Cbx-7, Bcl2, and P53 in Osteosarcoma Patients and Correlation With Clinicopathological Factors JO - Chemical Biology and Drug Design VL - 101 IS - 1 SP - 2 EP - 8 PY - 2023 ER -

Science Communicator Platform

Authors

Abstract